Amylyx Pharmaceuticals Stock News

NEW YORK , Oct. 6, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Amylyx insiders caused the company to misrepresent or fail to disclose that (i) RELYVRIO's commercial prospe...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares of common stock are being offered by Amylyx. In addition, Amylyx has granted the underwriters a 30-day option ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:50 PM EDT Company Participants Justin Klee - Co-Founder, Co-CEO & Director Joshua Cohen - Co-Founder, Co-CEO & Director Presentation Unknown Analyst Good afternoon. I'm just going to read this disclosure.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Citi's Biopharma Back to School Conference September 2, 2025 1:00 PM EDT Company Participants Joshua Cohen - Co-Founder, Co-CEO & Director Justin Klee - Co-Founder, Co-CEO & Director Presentation Unknown Analyst [Audio Gap] Question-and-Answer Session Joshua Cohen Co-Founder, Co-CEO & Director [Audio Gap] asset. It's a GLP-1 receptor antagonist.

Amylyx Pharmaceuticals said on Wednesday it will discontinue development of its experimental drug for a rare brain disorder after the treatment failed to show benefit in a mid-stage trial.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP).

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences.